MedTrace Logo

Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer

NCT02506790 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2019-09-04

No results posted yet for this study

Summary

This study evaluates the addition melatonin and metformin to toremifene in the treatment of locally advanced breast cancer. Third of patients will receive toremifene, other third will receive combination of melatonin and toremifene and other patients will receive combination of metformin and toremifene.

Conditions

Interventions

DRUG

metformin

DRUG

Melatonin

DRUG

Toremifene

Sponsors & Collaborators

  • N.N. Petrov National Medical Research Center of Oncology

    lead OTHER

Principal Investigators

  • Vladimir F Semiglazov, MD,PhD, DSc, Professor · N.N. Petrov Research Institute Of Oncology

  • Tatiana Y Semiglazova, MD, PhD, DSc · N.N. Petrov Research Institute Of Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2020-08-31
Completion
2022-08-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02506790 on ClinicalTrials.gov